12/06/2026 Sanofi’s Tzield approved in the US for patients recently diagnosed with stage 3 T1D Sanofi’s Tzield approved in the US for patients recently diagnosed with stage 3 T1D (Ref) Sanofi announced that the US FDA had granted accelerated approval to Tzield (teplizumab-mzwv; CD30directed mAb) to delay the decline in endogenous (own) insulin production in children aged eight to 17 years recently diagnosed with stage 3 T1D. The approval was supported by the Phase 3, PROTECT/